S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
66,000% upside on tiny biotech? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
66,000% upside on tiny biotech? (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
The single greatest medical breakthrough of all time? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
66,000% upside on tiny biotech? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
66,000% upside on tiny biotech? (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
The single greatest medical breakthrough of all time? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
66,000% upside on tiny biotech? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
66,000% upside on tiny biotech? (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
The single greatest medical breakthrough of all time? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
66,000% upside on tiny biotech? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
66,000% upside on tiny biotech? (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
The single greatest medical breakthrough of all time? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:ALXN

Alexion Pharmaceuticals (ALXN) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$182.50
▼
$182.50
50-Day Range
$179.45
▼
$186.61
52-Week Range
$99.91
▼
$187.45
Volume
10 shs
Average Volume
3.31 million shs
Market Capitalization
$40.34 billion
P/E Ratio
59.64
Dividend Yield
N/A
Price Target
N/A
ProfileFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

ALXN stock logo

About Alexion Pharmaceuticals (NASDAQ:ALXN) Stock

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.


ALXN Stock News Headlines

September 11, 2023 | msn.com
Alexion and Verge enter AI-powered drug discovery deal
May 13, 2023 | investing.com
Alexion Pharmaceuticals Inc (A1LX34)
September 24, 2023 | Behind the Markets (Ad)
BREAKING: The truth about war with China
Foreign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.
April 25, 2023 | marketwatch.com
Wilson Disease Drugs Market Size, Growth Strategies, Gross Margin and Forecast 2029
April 10, 2023 | thestreet.com
Alexion Reaches New 52-Week High (ALXN)
March 4, 2023 | stockhouse.com
Alexion advances commitment to transform patient outcomes in rare neurological diseases at AAN 2023
February 9, 2023 | investing.com
AstraZeneca goes for growth with new drugs as COVID sales wane
January 25, 2023 | seekingalpha.com
Healthcare Sector Is Lagging As We Enter 2022 Earnings Season
September 24, 2023 | Legacy Research (Ad)
WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
January 21, 2023 | thestreet.com
Synageva Biopharma (GEVA) Stock More Than Doubles to 52-Week High on Alexion Acquisition
October 14, 2022 | finance.yahoo.com
Alexion aims to advance NMOSD treatment landscape with exceptional ULTOMIRIS® (ravulizumab-cwvz) efficacy data at ECTRIMS 2022
September 15, 2022 | lse.co.uk
US close: Dow loses almost 1,300 points after hot CPI reading
September 1, 2022 | thestreet.com
Alexion Stock Hits New 52-Week High (ALXN)
July 29, 2022 | uk.investing.com
FTSE 100 positive but off best levels, US seen higher
March 17, 2022 | markets.businessinsider.com
AstraZeneca's Unit Alexion To Pay $775 Mln To Chugai On Ultomiris Patent Settlement
March 1, 2022 | uk.investing.com
AstraZeneca inks $760 million deal with Swiss firm Neurimmune for antibody drug
January 7, 2022 | msn.com
UK pre-market stocks update – Shell, AstraZeneca, Aston Martin, C&C
November 8, 2021 | finance.yahoo.com
Was The Smart Money Right About Piling Into Microchip Technology Incorporated (MCHP)?
October 26, 2021 | finance.yahoo.com
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexion Pharmaceuticals, Inc. (ALXN)
September 29, 2021 | feeds.benzinga.com
AstraZeneca Buys Fortress-Biotech Founded Caelum For $500M
September 29, 2021 | financialpost.com
AstraZeneca buys rare disease drugmaker Caelum in potential $500 mln deal
September 3, 2021 | law360.com
Alexion Must Face Claims Of Stalling On Drug After Merger
August 9, 2021 | finance.yahoo.com
Were Hedge Funds Right About Alexion Pharmaceuticals, Inc. (ALXN)?
July 24, 2021 | cnbc.com
Alexion Pharmaceuticals Inc ALXN-MX
July 23, 2021 | finance.yahoo.com
AstraZeneca Wraps Its Massive Alexion Buyout — Is AZN Stock A Buy Or Sell?
July 22, 2021 | finance.yahoo.com
Alexion Pharmaceuticals (ALXN) Earnings Expected to Grow: Should You Buy?
July 21, 2021 | finance.yahoo.com
ALXN vs. TECH: Which Stock Is the Better Value Option?
See More Headlines
Receive ALXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alexion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALXN Company Calendar

Last Earnings
4/29/2021
Today
9/24/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ALXN
CUSIP
01535110
CIK
899866
Web
www.alexion.com
Phone
475-230-2596
Fax
N/A
Employees
3,837
Year Founded
1992

Profitability

EPS (Most Recent Fiscal Year)
$11.60
Trailing P/E Ratio
59.64
Forward P/E Ratio
13.95
P/E Growth
0.93
Net Income
$603.40 million
Net Margins
10.89%
Pretax Margin
N/A
Return on Equity
23.43%
Return on Assets
15.06%

Debt

Debt-to-Equity Ratio
0.19
Current Ratio
4.52
Quick Ratio
3.96

Sales & Book Value

Annual Sales
$6.07 billion
Price / Sales
6.65
Cash Flow
$22.81 per share
Price / Cash Flow
8.00
Book Value
$53.24 per share
Price / Book
3.43

Miscellaneous

Outstanding Shares
221,019,000
Free Float
N/A
Market Cap
$40.34 billion
Optionable
Optionable
Beta
1.25

Social Links

10 Best Cheap Stocks to Buy Now Cover
10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Ludwig N. Hantson (Age 58)
    CEO & Director
    Comp: $4.25M
  • Dr. Aradhana Sarin M.D. (Age 46)
    Exec. VP & CFO
    Comp: $1.75M
  • Mr. Brian M. Goff (Age 52)
    Exec. VP and Chief Commercial & Global Operations Officer
    Comp: $1.76M
  • Ms. Ellen V. Chiniara J.D. (Age 62)
    Esq., Exec. VP, Chief Legal Officer & Corp. Sec.
    Comp: $1.56M
  • Dr. John J. OrloffDr. John J. Orloff (Age 64)
    Exec. VP and Head of R&D
    Comp: $1.83M
  • Mr. Daniel A. Bazarko CPAMr. Daniel A. Bazarko CPA
    Chief Accounting Officer & Sr. VP
  • Mr. Christopher J. Stevo CFA
    Head of Investor Relations
  • Ms. Indrani M. Lall FranchiniMs. Indrani M. Lall Franchini (Age 49)
    Exec. VP & Chief Compliance Officer
  • Megan Goulart
    Sr. Director of Corp. Communications
  • Ms. Becky Lillie
    Interim Chief Human Experience Officer

Key Competitors

View All Competitors













ALXN Stock - Frequently Asked Questions

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released its earnings results on Thursday, April, 29th. The biopharmaceutical company reported $3.52 earnings per share for the quarter, beating the consensus estimate of $3.16 by $0.36. The biopharmaceutical company earned $1.64 billion during the quarter, compared to analyst estimates of $1.58 billion. Alexion Pharmaceuticals had a net margin of 10.89% and a trailing twelve-month return on equity of 23.43%. The firm's revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.22 earnings per share.

What is Ludwig Hantson's approval rating as Alexion Pharmaceuticals' CEO?

43 employees have rated Alexion Pharmaceuticals Chief Executive Officer Ludwig Hantson on Glassdoor.com. Ludwig Hantson has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Alexion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU), AbbVie (ABBV), Tesla (TSLA), Broadcom (AVGO), Walt Disney (DIS) and Visa (V).

What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

What is Alexion Pharmaceuticals' stock price today?

One share of ALXN stock can currently be purchased for approximately $182.50.

How much money does Alexion Pharmaceuticals make?

Alexion Pharmaceuticals (NASDAQ:ALXN) has a market capitalization of $40.34 billion and generates $6.07 billion in revenue each year. The biopharmaceutical company earns $603.40 million in net income (profit) each year or $11.60 on an earnings per share basis.

How many employees does Alexion Pharmaceuticals have?

The company employs 3,837 workers across the globe.

Does Alexion Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Alexion Pharmaceuticals: Achillion Pharmaceuticals, Achillion Pharmaceuticals Inc., Alexion 1609 Partners LP, Alexion Bermuda Holding ULC, Alexion Bermuda II L.P., Alexion Bermuda L.P., Alexion Bermuda Limited, Alexion Bermuda Partners L.P., Alexion Business Services Private Limited, Alexion Delaware Holding LLC, Alexion Europe SAS, Alexion Farmacêutica América Latina Serviços de Administração de Vendas Ltda., Alexion Farmacêutica Brasil Importação e Distribuição de Produtos e Serviços de Administração de Vendas Ltda., Alexion Holding B.V., Alexion Holding LLC, Alexion Ilaç Ticaret Limited Þirketi, Alexion Pharma Argentina SRL, Alexion Pharma Austria GmbH, Alexion Pharma Belgium Sprl, Alexion Pharma Canada Corp., Alexion Pharma Colombia SAS, Alexion Pharma Czech s.r.o, Alexion Pharma Development Unlimited Company, Alexion Pharma Foreign Holdings B.V., Alexion Pharma France SAS, Alexion Pharma GK, Alexion Pharma Germany GmbH, Alexion Pharma GmbH, Alexion Pharma Holding Unlimited Company, Alexion Pharma International Operations Unlimited Company, Alexion Pharma Israel Ltd., Alexion Pharma Italy Sarl, Alexion Pharma Korea LLC, Alexion Pharma LLC, Alexion Pharma Mexico S. de R.L. de C.V., Alexion Pharma Middle East FZ-LLC, Alexion Pharma Netherlands B.V., Alexion Pharma Nordics AB, Alexion Pharma Nordics Holding AB, Alexion Pharma OOO LLC, Alexion Pharma Spain S.L., Alexion Pharma Taiwan LTD, Alexion Pharma UK Ltd., Alexion Pharmaceuticals (Shanghai) Company Limited, Alexion Pharmaceuticals Australasia PTY LTD, Alexion Services Europe Sprl, Alexion Services Latin America Inc., Alexion US Holdings LLC, Alexion US1 LLC, Enobia Pharma Corp., Portola Deutschland GmbH, Portola FRG GmbH, Portola Italia S.r.l., Portola Netherlands B.V., Portola Pharma UK Ltd., Portola Pharmaceuticals Espana S.L, Portola Pharmaceuticals Inc., Portola Pharmaceuticals LLC, Portola Schweiz GmbH, Portola USA Inc., Portola Österreich GmbH, Savoy Therapeutics Corp., Synageva BioPharma Corp., Syntimmune, Syntimmune Ltd., TTM Europe Development AB, Taligen Therapeutics Inc., Wilson Therapeutics, Wilson Therapeutics AB, Wilson Therapeutics Incentive AB, and Wilson Therapeutics USA Inc..
Read More
How can I contact Alexion Pharmaceuticals?

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The official website for the company is www.alexion.com. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at investorrelations@alexion.com.

This page (NASDAQ:ALXN) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -